PharmaPoint: Hepatitis C Virus – Brazil Drug Forecast and Market Analysis to 2022

Publisher Name :
Date: 31-May-2013
No. of pages: 109

Summary

GlobalData has released its new Country report, “PharmaPoint: Hepatitis C Virus – Brazil Drug Forecast and Market Analysis to 2022″. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche’s Pegasys and Merck’s PegIntron) and ribavirin (e.g., Roche’s Copegus and Merck’s Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease inhibitor added to their combination therapy, such as Merck’s Victrelis (boceprevir) or Vertex’s Incivek (telaprevir). The entrance of next-generation HCV therapies is expected to fundamentally change the HCV treatment algorithm. GlobalData expects a dramatic shift favoring the uptake of interferon-free regimens due to their more tolerable side-effect profiles and decreased duration of therapy compared with the current standard of care.

The anticipated drivers of growth of the HCV market in Brazil include increasing awareness of the disease, the adoption of non-invasive liver diagnostic tests, and the launch of next-generation HCV therapies.

Roche’s Pegasys (peginterferon alfa-2a) is the current market leader in Brazil. Pegasys was launched in Brazil after Merck’s PegIntron (peginterferon alfa-2b), but GlobalData believes that Pegasys was able to quickly dominate the market due to a perceived better side effect profile and efficacy. Sales of both Pegasys and PegIntron are projected to increase in Brazil as a result an increase in the country’s HCV treatment rate. Sales of both drugs are also expected to be boosted by their drug’s inclusion in triple therapies (i.e., DAA, peginterferon, and ribavirin).

Scope

  • Overview of the HCV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Brazil including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Brazil from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting Brazil HCV market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for HCV
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in Brazil

PharmaPoint: Hepatitis C Virus – Brazil Drug Forecast and Market Analysis to 2022

Table Of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9

2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
2.3 Upcoming Related Reports 11

3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 16
3.1.3 Prognosis 17
3.2 Symptoms 17

4 Disease Management 18
4.1 Diagnosis and Referral Overview 18
4.2 Treatment Overview 19
4.3 Brazil 22
4.3.1 Diagnosis 22
4.3.2 Clinical Practice 22

5 Competitive Assessment 23
5.1 Overview 23
5.2 Strategic Competitor Assessment 23
5.3 Product Profiles - Major Brands 25
5.3.1 Incivek (telaprevir) 25
5.3.2 Victrelis (boceprevir) 30
5.3.3 Pegasys (peginterferon alfa-2a) 34
5.3.4 PegIntron (peginterferon alfa-2b) 38
5.3.5 Copegus, Rebetol, and Generic Ribavirin 42
5.3.6 Therapeutic Class: Interferon 44

6 Opportunity and Unmet Need 45
6.1 Overview 45
6.2 Unmet Needs 46
6.2.1 Unmet Need: Treatment Tolerability 46
6.2.2 Unmet Need: Efficacy 46
6.2.3 Unmet Need: Disease Awareness 47
6.2.4 Unmet Need: Treatment Cost 48
6.2.5 Unmet Need: Shorter Treatment Duration 48
6.2.6 Unmet Need: Simplified Treatment Regimens 49
6.3 Unmet Needs Gap Analysis 49
6.4 Opportunities 50
6.4.1 Opportunity: Pan-genotypic HCV Regimen 50
6.4.2 Opportunity: Treatment of Underrepresented Patient Populations 50
6.4.3 Opportunity: Involvement of Immune System 51

7 Pipeline Assessment 52
7.1 Overview 52
7.2 Promising Drugs in Clinical Development 53
7.2.1 Simeprevir 55
7.2.2 Faldaprevir and Faldaprevir plus BI 207127 62
7.2.3 Daclatasvir and Daclatasvir plus Asunaprevir 70
7.2.4 Other Drug Classes 77

8 Market Outlook 81
8.1 Brazil 81
8.1.1 Forecast 81
8.1.2 Key Events 85
8.1.3 Drivers and Barriers 85

9 Appendix 88
9.1 Bibliography 88
9.2 Abbreviations 96
9.3 Methodology 98
9.4 Forecasting Methodology 98
9.4.1 Percent Drug-Treated Patients 98
9.4.2 Patient Warehousing 99
9.4.3 Drugs Included in Each Therapeutic Class 99
9.4.4 General Pricing Assumptions 99
9.4.5 Individual Drug Assumptions 100
9.4.6 Generic Erosion 102
9.4.7 Selection of Pipeline Agents 102
9.4.8 Pricing of Pipeline Agents 103
9.5 Physicians and Specialists Included in this Study 105
9.6 Survey of Prescribing Physicians 107
9.7 About the Authors 108
9.7.1 Author 108
9.7.2 Global Head of Healthcare 108
9.8 About GlobalData 109
9.9 Contact Us 109
9.10 Disclaimer 109

List Of Tables

Table 1: Modes of HCV Transmission 16
Table 2: Symptoms of Acute and Chronic HCV Infection 17
Table 3: HCV Genotypes Present in the 9MM 19
Table 4: General Standard of Care by HCV Genotype 19
Table 5: Treatment Guidelines for HCV by Country 20
Table 6: Most-Prescribed Drugs for HCV by Class in the Global Markets, 2013 21
Table 7: Leading Treatments for HCV, 2012 24
Table 8: Product Profile - Incivek 26
Table 9: Efficacy of Incivek in Treatment-Naïve Patients (ADVANCE Trial) 26
Table 10: Efficacy of Incivek in Treatment-Experienced Patients (REALIZE Trial) 27
Table 11: Common Incivek Adverse Drug Reactions 28
Table 12: Incivek SWOT Analysis, 2012 29
Table 13: Product Profile - Victrelis 30
Table 14: Victrelis Efficacy in Treatment-Naïve Patients (SPRINT-2 Trial) 31
Table 15: Victrelis Efficacy in Treatment-Experienced Patients (RESPOND-2 Trial) 32
Table 16: Victrelis SWOT Analysis, 2012 34
Table 17: Product Profile - Pegasys 35
Table 18: Antiviral Efficacy of Peginterferon alfa-2a Compared with Interferon alfa-2b 36
Table 19: Pegasys SWOT Analysis, 2012 38
Table 20: Product Profile - PegIntron 39
Table 21: Antiviral Efficacy of Peginterferon alfa-2b Compared with Interferon alfa-2b 40
Table 22: PegIntron SWOT Analysis, 2012 41
Table 23: Effect of Addition of Ribavirin to Peginterferon HCV Therapy 43
Table 24: Ribavirin SWOT Analysis, 2012 44
Table 25: Summary of Minor Therapeutic Classes, 2012 44
Table 26: Overall Unmet Needs - Current Level of Attainment 45
Table 27: Clinical Unmet Needs - Gap Analysis, 2012 49
Table 28: HCV - Pipeline, 2012 53
Table 29: Comparison of Therapeutic Classes in Development for HCV, 2012 55
Table 30: Janssen's Simeprevir Ongoing Clinical Trials of Interest 56
Table 31: Product Profile - Simeprevir 57
Table 32: PILLAR Clinical Trial Results 57
Table 33: Adverse Events Observed in PILLAR Clinical Trial 58
Table 34: Simeprevir SWOT Analysis, 2012 61
Table 35: Boehringer Ingelheim's Faldaprevir Ongoing Clinical Trials of Interest 63
Table 36: Product Profile - Faldaprevir 64
Table 37: Efficacy of Interferon-Free Faldaprevir Regimen (SOUND-C2 Trial) 65
Table 38: Faldaprevir SWOT Analysis, 2012 69
Table 39: Bristol-Myers Squibb's Daclatasvir Ongoing Clinical Trials of Interest 71
Table 40: Product Profile - Daclatasvir 72
Table 41: Efficacy of Daclatasvir in Treatment-Naïve Patients (COMMAND-1 Trial) 72
Table 42: Daclatasvir and Asunaprevir Quad Therapy Efficacy 73
Table 43: Daclatasvir Triple Therapy Adverse Events 74
Table 44: Daclatasvir SWOT Analysis, 2012 77
Table 45: Comparison of Peginterferon lambda with Peginterferon alfa (EMERGE Trial) 78
Table 46: Efficacy of Alisporivir in Treatment-Naïve HCV GT2/3 Patients (VITAL-1 Trial) 79
Table 47: Sales Forecasts ($m) for HCV in Brazil, 2012-2022 83
Table 48: Key Events Impacting Sales for HCV in Brazil, 2012 85
Table 49: Brazilian HCV Market - Drivers and Barriers, 2012 85
Table 50: Physicians Surveyed, By Country 107

List Of Figures

Figure 1: HCV Genome and Polyprotein Composition 13
Figure 2: HCV Lifecycle Overview 14
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in HCV, 2012-2022 54
Figure 4: Sales for HCV Therapeutics in Brazil by Drug Class, 2012-2022 84

  • Water Treatment Chemicals Market to be driven by Increasing Demand from Developing Economies
    The global market for water treatment chemicals is growing at a steady pace with rapid urbanization and high demand from end-users. Water treatment chemicals are used for treating municipal water as well as agricultural wastewater. With higher demand for clean, drinking water with increasing population and increase in the number of industries, the global market [...]
  • Rise in Prevalence of Allergic Diseases Driving the Global Allergy Diagnostics Market
    With rise in the incidences of allergic diseases in the world, the global allergy diagnostics market has also witnessed steady growth. In recent years, there has been an increase in the number of people suffering from different allergies, particularly food allergies and drug allergies. The number of people suffering from asthma has also increased in [...]
  • Global Video Surveillance Market Driven by Increasing Demand for Security
    The global market for video surveillance has been witnessing steady growth with increase in demand for advanced surveillance systems by different law enforcement agencies. Increase in adoption of video surveillance by different sectors such as banking and finance, healthcare, transportation, and retail is one of the major drivers in the market. In 2013, the global [...]
  • Global Empty Capsules Market Driven by Growth in Pharmaceutical Industry
    With rapid growth in the pharmaceutical industry, the market for empty capsules has also grown at a steady pace. Some of the factors which are driving the growth of the empty capsules market are rise in aging population which is increasing the demand for capsule based drugs, technological advancement and increase in demand from the [...]
  • Global Aramid Fiber Industry to Witness High Growth in the Future
    With increasing use of aramid fibers in various industries, the global market for aramid fibers has grown significantly in recent years. Aramid fibers have a number of properties such as low density, heat resistance, high tensile strength, abrasion resistance, chemical resistance and impact resistance.  Asia-Pacific is the largest market for aramid fibers, followed by North [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Myasthenia Gravis – Pipeline Review, H2 2014
    Published: 10-Dec-2014        Price: US $2000 Onwards        Pages: 93
    Global Markets Direct's, ‘Myasthenia Gravis Pipeline Review, H2 2014', provides an overview of the Myasthenia Gravis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Myasthenia Gravis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key......
  • Sarcoidosis – Pipeline Review, H2 2014
    Published: 10-Dec-2014        Price: US $2000 Onwards        Pages: 61
    Global Markets Direct's, ‘Sarcoidosis Pipeline Review, H2 2014', provides an overview of the Sarcoidosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Sarcoidosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved ......
  • Osteoporosis Drugs Market in the APAC Region 2015-2019
    Published: 3-Dec-2014        Price: US $2500 Onwards        Pages: 73
    Osteoporosis is a disease that reduces of the mass and density of bone, and results in increased risk of fracture. In this disease, the risks related to fracture increases because of the increased permeability of the bones. Often, there are no symptoms observed until the first fracture occurs. Increase in age, low body weight, low sex hormones or menopause, and smoking are some of the risk factors associated with this disease. TechNavio's analysts forecast the Osteoporosis Drugs market in APA......
  • Global Multiple Myeloma Drugs Market 2015-2019
    Published: 3-Dec-2014        Price: US $3000 Onwards        Pages: 115
    Multiple myeloma is a common cancer that affects the plasma cells, a type of white blood cell. It begins in the plasma cells of bone marrow. The primary function of the plasma cells is to combat infections by producing antibodies, which attack germs after recognizing them. In multiple myeloma these plasma cells become malignant, it causes the production of a defective protein, which grows uncontrollably. This protein moves into the bones and cause tumors. Myeloma occurs when the malignant cells ......
  • Global Excipients Market 2014-2018
    Published: 3-Dec-2014        Price: US $2500 Onwards        Pages: 82
    Excipients are pharmacologically inactive substances used in the form of a carrier with the active ingredient of a medication. Excipients help stabilize the active ingredient of a drug for a longer period and are used as a bulking up agent in drug formulations. Excipients are classified primarily based on their product type, functionality, and category. The Global Excipients market is highly fragmented with multiple active vendors. TechNavio's analysts forecast the Global Excipients market to......
  • Replagal-Drug Insights,2014
    Published: 2-Dec-2014        Price: US $1000 Onwards        Pages: 36
    Summary DelveInsight's pharmaceuticals report, "Replagal - Drug Insights, 2014" provides Replagal marketed details and API Manufacturers details across the globe along with the location. In addition, it covers sales estimates for the US, detailed clinical assessment of the drug, patent details, route of synthesis, competitive landscape, and analysis of sales performance during the forecast period (2011-2015). The report also includes SWOT analysis for the drug. This report is built using data......
  • EpiCast Report: Rheumatoid Arthritis – Epidemiology Forecast to 2023
    Published: 1-Dec-2014        Price: US $3995 Onwards        Pages: 48
    Rheumatoid arthritis (RA) is an autoimmune disease that causes inflammation of the joints. In RA, the body's immune system attacks the lining of the joints causing an inflammatory response. RA is characterized by joint swelling, pain, and redness, which can cause bone and cartilage erosion, and joint deformity. The disease can lead to premature mortality, disability, and decreased quality of life. GlobalData epidemiologists forecast an increase in the total prevalent cases of RA in the 8MM, f......
  • Osteoporosis Drugs Markets in China
    Published: 1-Dec-2014        Price: US $4000 Onwards        Pages: 175
    China's demand for Osteoporosis Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, ......
  • EpiCast Report: Colorectal Cancer – Epidemiology Forecast to 2023
    Published: 1-Dec-2014        Price: US $3995 Onwards        Pages: 54
    Colorectal cancer (CRC) is cancer that starts in the colon or the rectum. CRC has the third highest incidence among all cancers in men and second highest in women. CRC is a high mortality cancer, with mortality rates just behind lung, liver, and stomach cancers in men, and breast and lung cancers in women. Most cases of CRC start as small adenoma polyps in the inner lining of the colon or rectum. CRC screening aims to identify and remove polyps when they are small to prevent the polyps from chan......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs